Decrease RTR, IR, and CR Due to Dissolution Deficiencies (21of28) GDF - Apr. 3-4, 2019

  Рет қаралды 1,812

U.S. Food and Drug Administration

U.S. Food and Drug Administration

Күн бұрын

Пікірлер
Impurity Case Studies: Pharmacology/Toxicology (22of28) Generic Drugs Forum - Apr. 3-4, 2019
25:40
U.S. Food and Drug Administration
Рет қаралды 1,8 М.
Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA
1:56:59
U.S. Food and Drug Administration
Рет қаралды 10 М.
VIP ACCESS
00:47
Natan por Aí
Рет қаралды 30 МЛН
Cat mode and a glass of water #family #humor #fun
00:22
Kotiki_Z
Рет қаралды 42 МЛН
So Cute 🥰 who is better?
00:15
dednahype
Рет қаралды 19 МЛН
Dissolution Method Development for Generic Drugs (24/28) Generic Drugs Forum 2017
15:23
U.S. Food and Drug Administration
Рет қаралды 6 М.
In Vitro Drug Release Testing for LA Drug Products QC (16of35) Complex Generics - Sep. 25-26, 2019
16:57
An In-Depth Look at the Final FDA Guidance: Bioavailability Studies Submitted in NDAs or INDs
2:35:24
Regulatory Considerations for Impurity Qualification: ICH Q3A/Q3C/Q3D, RLD & MDD
28:12
U.S. Food and Drug Administration
Рет қаралды 10 М.
Biopharmaceutics Risk Assessment to Guide Dissolution Method Development for Solid Oral Dosage Forms
21:57
Division of Filing Review: Helpful Tips for Submission of an ANDA or Controlled Correspondence
23:35
FDA Clinical Investigator Training Course (CITC) 2024 - Day One - Session Two
1:42:25
U.S. Food and Drug Administration
Рет қаралды 1,6 М.
FDA Clinical Investigator Training Course (CITC) 2024 - Day One - Session One
2:14:51
U.S. Food and Drug Administration
Рет қаралды 879
FDA Clinical Investigator Training Course (CITC) 2024 - Day Three - Session One
1:43:17
U.S. Food and Drug Administration
Рет қаралды 376
VIP ACCESS
00:47
Natan por Aí
Рет қаралды 30 МЛН